OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma
OS Therapies reported statistically significant 2.5-year overall survival data for its lead asset OST-HER2 in metastatic osteosarcoma, showing 75% survival versus 47% in pooled historical controls (p=0.003). No new patient deaths were reported in the treatment group between the 2-year and 2.5-year timepoints, suggesting durability of the clinical benefit.
Key figures
- Drug Name
- OST-HER2
- Phase Of Trial
- Phase 2b
- P value 2yr
- 0.034
- P value 2 5yr
- 0.003
- Overall survival 2yr control
- 60%
- Overall survival 2 5yr control
- 47%
- Overall survival 2yr treatment
- 75%
- Overall survival 2 5yr treatment
- 75%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.